



Date: 16-01-2021

To
Corporate Relation Department
BSE Limited
P. J. Tower, Dalal Street,
Mumbai – 400 001

To
Listing Department
Metropolitan Stock Exchange of India Ltd
4th floor, Vibgyor tower,
Opposite Trident Hotel,
Bandra- Kurla Complex, Mumbai - 400098

Dear Sir / Madam,

Sub: Outcome of the Board Meeting held today i.e 16th January 2021

Further to our intimation dated 08th January, 2021 and pursuant to Regulation 30 and 42 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at their meeting held today, i.e., 16th January, 2021, has approved inter-alia

Un-audited Financial Results:

the Unaudited Financial Results of the Company for the quarter ended 31st December, 2020. A copy of the Unaudited Financial Results as per SEBI format and the Limited Review Report of the Statutory Auditors of the Company for the quarter ended 31st December, 2020 are enclosed pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Issue of Bonus Shares:

1. The Board has recommended the issuance of Bonus Shares of the Company in the ratio of 2 (Two) new Bonus Equity Share of Rs. 10 each fully paid up to be issued for every 1 (One) existing Equity Share of Rs. 10 each fully paid up held by the shareholders on the record date subject to the approval of the Shareholders by Postal ballot / remote e-voting. The details required to be given in terms of SEBI Circular no. CIR/CFD/CMD/4/2015 dated 9th September, 2015 for bonus issue is enclosed herewith as Annexure A.
2. Equity shares of the Company are currently listed on BSE Limited and Metropolitan Stock Exchange of India Limited. However, due to small capital base, company's shares are permitted by BSE Ltd for trading under "Periodic Call Auction Session" (PCAS). Therefore, for facilitating ease of trading, increasing liquidity, shareholder value and encouraging participation of investors, the company considers it necessary to enhance its paid-up share capital beyond Rs. 10 crores in order to get qualified for trading on the Main Trading Board of BSE Ltd.



Smruthi Organics Limited

3. The Company will intimate the "Record date" for determining eligible shareholders entitled to receive Bonus Shares, in due course.
4. The Board also recommended to shareholders, reclassification of unissued preference share capital into equity shares, increase the authorised share capital from Rs 10,00,00,000/- to Rs. 12,00,00,000/- and approve consequential alterations to the Memorandum of Association and Articles of Association.

Further, the Board Meeting commenced at 11.00 am and concluded at 12.10 p.m.

Kindly take on record the above information and acknowledge.

For Smruthi Organics Ltd

E. Purushotham
Chairman & Managing Director
DIN: 00033583





Smruthi Organics Limited

Annexure — A: Details required for bonus issue as per Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulation, 2015:

S. No	Particulars	Remarks
1	Whether bonus is out of free reserves created out of profits or share premium account/ Retained Earnings	Yes
2	Bonus Ratio	2 (Two) new Bonus Equity Share of Rs. 10 each fully paid up to be issued for every 1 (One) existing Equity Share of Rs. 10 each fully paid up.
3	Details of share capital — Pre and Post issue	The pre-bonus issue paid-up equity share capital as on the date of this letter is Rs. 3,81,54,300/- consisting of 38,15,430 equity shares of Rs. 10 each The post bonus paid-up equity share capital shall be Rs. 11,44,62,900/- consisting of 1,14,46,290 equity shares of Rs. 10 each.
4	Free reserves and / or share premium / Retained Earnings required for implementing the bonus issue	Rs 7,63,08,600/-
5	Free reserves and / or share premium / Retained Earnings available for capitalization and the date as on which such balance is available	Rs 38,43,72,577/- As on 31 st March, 2020
6	Whether the aforesaid figures are audited	Yes
7	Estimated date by which such bonus shares would be credited / dispatched	20 th March, 2021

For Smruthi Organics Ltd

E. Purushotham
Chairman & Managing Director
DIN: 00033583



N. R. Waghchaure & Associates
Chartered Accountants
16-22, Royal Plaza,
Murarji Peth, Solapur – 413001
Ph: 0217-2625054 Cell: 9423590501
Email: fcanrw1970@gmail.com

Annex 2

Limited Review Report on unaudited Standalone Financial Results of Smruthi Organics Limited for Nine Months ended 31st December 2020 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We have reviewed the accompanying statement of unaudited financial results of Smruthi Organics Limited for the period ended 31st December 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Solapur
Date: 16.01.2021



N.R. Waghchaure & Associates.
Chartered Accountants


N.R. Waghchaure
Proprietor
FRN - 114999W

UDIN : 21048890AAAAAS8476

Smruthi Organics Limited

Registered & Corporate Office: 165-A, Balaji Bhavan, 1st Floor, Railway Lines, Solapur - 413001

CIN :- L24119PN1989PLC052562

STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR NINE MONTHS ENDED 31st DECEMBER 2020

PART I

Sr. No.	Particulars	(Rs. In Lakhs)									
		Quarter Ended		Nine Months ended		Year ended					
		Current Year	Previous Year	Current Year	Previous Year	Current Year	Previous Year				
		30.12.2020	31.12.2019	31.12.2020	31.12.2019	31.12.2020	31.12.2019				
		(Un-audited)	(Un-audited)	(Un-audited)	(Un-audited)	(Un-audited)	(Un-audited)				(Audited)
1	Income from Operations										
	a) Revenue from Operations	3159.26	3077.08	9778.22	10109.07	13107.36	10109.07				
	b) Other Income	22.68	412.04	37.61	420.98	442.14	420.98				
	Total Revenue from Operations & Other Income (a+b)	3181.94	3489.12	9815.83	10530.05	13549.50	10530.05				
2	Expenses										
	a) Cost of Materials Consumed	1433.36	1840.76	4874.21	5826.89	7808.99	5826.89				
	b) Changes in Inventories of Finished Goods, Work-in-Progress	85.86	346.15	277.09	822.75	539.38	822.75				
	c) Employee Benefits Expense	439.47	368.76	1171.15	1038.19	1357.14	1038.19				
	d) Finance Costs	21.05	78.39	86.55	255.83	318.05	255.83				
	e) Depreciation and Amortisation Expenses	81.86	111.00	304.36	315.00	438.63	315.00				
	f) Other Expenses	392.13	440.92	1147.98	1398.86	1878.16	1398.86				
	TOTAL Expenses (a+b+c+d+e+f)	2453.73	3185.98	7861.34	9657.52	12340.35	9657.52				
3	Profit / (Loss) before Exceptional Items and Tax	728.21	303.14	1954.49	872.53	1209.15	872.53				
4	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00				
5	Profit / (Loss) before tax (3 - 4)	728.21	303.14	1954.49	872.53	1209.15	872.53				
6	Tax Expense										
	a) Current Income Tax (See Note No. 5 below)	167.05	55.00	427.91	182.00	211.27	182.00				
	b) MAT Credit Entitlement	47.52	0.00	148.35	0.00	86.54	0.00				
	c) Deferred Tax (Asset) / Liability	2.73	6.00	(15.16)	38.00	66.62	38.00				
	Total Tax Expenses	217.30	61.00	561.10	220.00	364.43	220.00				
7	Net Profit/(Loss) for the period (5 - 6)	510.91	242.14	1393.39	652.53	844.72	652.53				



8	Other Comprehensive Income								
	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-
	(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
	(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	-	-	-	-	-	-	-
9	Total Comprehensive Income (7 + 8)	510.91	583.98	242.14	1393.39	652.53	844.72		
10	Paid-up Equity Share Capital (Face value of Rs. 10/- each)	381.54	381.54	381.54	381.54	381.54	381.54		
11	Earnings per Equity Share (not annualised)								
	a) Basic	13.39	15.31	6.35	36.52	17.10	22.14		
	b) Diluted	13.39	15.31	6.35	36.52	17.10	22.14		

Note:



- The entire operations of the Company constitute a single operating segment i.e. Bulk Drugs and Drug Intermediates.
- The Statutory Auditor have carried out the Limited Review of Un-audited financial results of the Company for the Nine Months ended on 31st December 2020.
- The above financials were reviewed by the Audit Committee and Approved by the Board of Directors at meeting held on 16th January 2021.
- Sales includes Revenue from Operations for the nine months ended 31st December 2020 is net of Goods and Service Tax(GST).
- Provision for Income Tax is calculated at normal rate of tax.
- The financial results are prepared in accordance with the Indian Accounting Standards (Ind AS) 108 as prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- There is no impact on net profit/loss, total comprehensive income or any other relevant financial items due to change in accounting policies.
- The Board approved the issue of Bonus Shares in the ratio of Two new Equity Shares of the face value of Rs. 10 each fully paid up for every One existing Equity Share of Rs. 10 each fully paid up subject to the approval of shareholders through Postal Ballot.
- Previous period's figures have been regrouped / rearranged wherever necessary to conform to the current period's classification.



Place Solapur
Date 16.01.2021



(Handwritten Signature)

E. PURUSHOTHAM
CHAIRMAN & MANAGING DIRECTOR
DIN: 00033583





Notes: The company has launched 1 new API product, Teneigiptin (anti – diabetes), in the current quarter